These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17720663)

  • 21. Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir.
    van Griensven J; Zachariah R; Rasschaert F; Atté EF; Reid T
    Trans R Soc Trop Med Hyg; 2009 Jun; 103(6):613-9. PubMed ID: 18835003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.
    Martin A; Smith DE; Carr A; Ringland C; Amin J; Emery S; Hoy J; Workman C; Doong N; Freund J; Cooper DA;
    AIDS; 2004 Apr; 18(7):1029-36. PubMed ID: 15096806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.
    Ribera E; Larrousse M; Curran A; Negredo E; Clotet B; Estrada V; Sanz J; Berenguer J; Rubio R; Pulido F; Ferrer P; Alvarez ML; Arterburn S; Martínez E
    HIV Med; 2013 Jul; 14(6):327-36. PubMed ID: 23298339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of lipoatrophy and aging: volume deficits in the face.
    Coleman S; Saboeiro A; Sengelmann R
    Aesthetic Plast Surg; 2009 Jan; 33(1):14-21. PubMed ID: 18987910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in body fat measured by DEXA in patients taking different formulations of stavudine.
    Yang Y; Wilder-Smith A; Panchalingam A; Tha NO; Paton NI
    HIV Clin Trials; 2005; 6(6):337-43. PubMed ID: 16452067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
    Podzamczer D; Ferrer E; Sanchez P; Gatell JM; Crespo M; Fisac C; Lonca M; Sanz J; Niubo J; Veloso S; Llibre JM; Barrufet P; Ribas MA; Merino E; Ribera E; Martínez-Lacasa J; Alonso C; Aranda M; Pulido F; Berenguer J; Delegido A; Pedreira JD; Lérida A; Rubio R; del Río L;
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):139-47. PubMed ID: 17106274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.
    van Griensven J; De Naeyer L; Mushi T; Ubarijoro S; Gashumba D; Gazille C; Zachariah R
    Trans R Soc Trop Med Hyg; 2007 Aug; 101(8):793-8. PubMed ID: 17467756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.
    Hammond E; McKinnon E; Nolan D
    Clin Infect Dis; 2010 Sep; 51(5):591-9. PubMed ID: 20645860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.
    Saint-Marc T; Partisani M; Poizot-Martin I; Bruno F; Rouviere O; Lang JM; Gastaut JA; Touraine JL
    AIDS; 1999 Sep; 13(13):1659-67. PubMed ID: 10509567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population.
    Lichtenstein KA; Ward DJ; Moorman AC; Delaney KM; Young B; Palella FJ; Rhodes PH; Wood KC; Holmberg SD;
    AIDS; 2001 Jul; 15(11):1389-98. PubMed ID: 11504960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipoatrophy of the footpad in HIV-treated patients is associated with increased PAI-1.
    Eriksson LE; Nilsson Schönnesson L; Bratt GA
    Biol Res Nurs; 2011 Jan; 13(1):89-96. PubMed ID: 19942593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz.
    Viganò A; Brambilla P; Cafarelli L; Giacomet V; Borgonovo S; Zamproni I; Zuccotti G; Mora S
    Antivir Ther; 2007; 12(3):297-302. PubMed ID: 17591019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics and factors associated with the clinical forms of lipoatrophy during highly active antiretroviral therapy in Ouagadougou, Burkina Faso.
    Guira O; Tiéno H; Yaméogo B; Diendéré AE; Korsaga N; Sagna Y; Zoungrana L; Diallo I; Traoré R; Drabo JY
    J Int Assoc Provid AIDS Care; 2014; 13(2):184-7. PubMed ID: 24114724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine.
    Arpadi SM; Cuff PA; Horlick M; Wang J; Kotler DP
    J Acquir Immune Defic Syndr; 2001 May; 27(1):30-4. PubMed ID: 11404517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine.
    Cherry CL; Lal L; Thompson KA; McLean CA; Ross LL; Hernandez J; Wesselingh SL; McComsey G
    J Acquir Immune Defic Syndr; 2005 Mar; 38(3):263-7. PubMed ID: 15735442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
    Cournil A; Coudray M; Kouanfack C; Essomba CN; Tonfack CA; Biwolé-Sida M; Delaporte E; Bork K; Laurent C
    Antivir Ther; 2010; 15(7):1039-43. PubMed ID: 21041920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
    Parruti G; Toro GM
    BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
    Moyle GJ; Sabin CA; Cartledge J; Johnson M; Wilkins E; Churchill D; Hay P; Fakoya A; Murphy M; Scullard G; Leen C; Reilly G;
    AIDS; 2006 Oct; 20(16):2043-50. PubMed ID: 17053350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study).
    Martin A; Smith D; Carr A; Hoy J; Chuah J; Mallal S; Law M; Clements M; Cooper DA;
    HIV Clin Trials; 2004; 5(4):192-200. PubMed ID: 15472793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.
    Nolan D; Hammond E; James I; McKinnon E; Mallal S
    Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.